Q4 2027
Ends Dec 31, 2027
Revenue
$0.1B
$0.1B to $0.1B
EPS
-0.67
-0.67 to -0.67
No analyst count
EPS: No analyst count
Apr 27, 01:07 PM UTC
stable/analyst-estimates
Healthcare
Live Price
Offline$36.29
+0.03% today
1Y Change
+72.60%
Window
Jun 30, 2025 → Jun 24, 2026
Coverage: 247 bars · Jun 30, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
IDEAYA Biosciences, Inc. (IDYA) is a Healthcare stock with a market cap of $2.56B and listed on NASDAQ. The stock last traded around $36.29 and up 72.6% across the available one-year price window (Jun 30, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of +3024.4%, EPS growth of +61.9%, a dividend yield of 0.0%. What stands out right now is revenue +3024.4%, EPS +61.9%, free cash flow +70.8% with operating margin -72.8% and ROIC -15.2%. Valuation already assumes a fairly strong business story at price/sales 11.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines IDYA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
IDYA is 53.92 pts ahead over the shared 1Y window.
IDYA had 17.97 pts deeper max drawdown than SPY.
IDYA beat SPY in 2 of 2 calendar years shown and trailed in 0.
IDYA
+72.60%
Normalized return
SPY
+18.68%
S&P 500
Excess Return
+53.92 pts
Relative to SPY
IDYA Max Drawdown
-27.10%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for IDYA and SPY.
| Year | IDYA | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +7.18% | +6.71% | +0.47 pts | IDYA |
| 2025 | +64.18% | +11.19% | +52.98 pts | IDYA |
EPS Consensus
-0.67
Range -0.67 -> -0.67
No analyst count
vs prior: +19.9%Revenue Outlook
$0.1B
Range $0.1B -> $0.1B
No analyst count
vs prior: +58.9%Price Target
--
-- -> --
No analyst count
Recommendations
--
No recommendation feed
No date
Consensus Spread
Lower spread suggests tighter agreement across covering analysts.
Next Earnings
EPS --
Revenue --
No analyst count
EPS Revisions
No recent EPS revision rows
0 revision rows
Trend
Consensus average across visible periods
Trend
Average analyst revenue estimate
Timeline
Sorted by period end date. Includes both cached rows and live fallbacks from the configured analyst feed.
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.